HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,160,133 | -26.1% | 108,904 | -30.2% | 0.00% | 0.0% |
| Q2 2023 | $5,626,018 | -26.0% | 155,975 | -21.6% | 0.00% | -25.0% |
| Q1 2023 | $7,599,504 | -31.5% | 198,992 | +2.1% | 0.00% | -33.3% |
| Q4 2022 | $11,092,484 | +68.4% | 194,947 | +17.0% | 0.01% | +50.0% |
| Q3 2022 | $6,586,000 | +73.0% | 166,561 | +92.5% | 0.00% | +100.0% |
| Q2 2022 | $3,807,000 | -2.3% | 86,522 | -11.4% | 0.00% | 0.0% |
| Q1 2022 | $3,896,000 | -13.0% | 97,681 | -12.2% | 0.00% | 0.0% |
| Q4 2021 | $4,476,000 | +5.1% | 111,307 | +6.3% | 0.00% | 0.0% |
| Q3 2021 | $4,259,000 | -43.5% | 104,690 | -37.0% | 0.00% | -50.0% |
| Q2 2021 | $7,544,000 | -12.9% | 166,147 | -20.0% | 0.00% | -20.0% |
| Q1 2021 | $8,661,000 | -40.4% | 207,750 | -39.0% | 0.01% | -44.4% |
| Q4 2020 | $14,541,000 | -3.8% | 340,426 | -40.8% | 0.01% | -10.0% |
| Q3 2020 | $15,121,000 | +51.3% | 575,404 | +54.4% | 0.01% | +25.0% |
| Q2 2020 | $9,994,000 | -0.9% | 372,776 | -33.5% | 0.01% | -11.1% |
| Q1 2020 | $10,088,000 | -21.6% | 560,779 | -22.7% | 0.01% | +12.5% |
| Q4 2019 | $12,866,000 | +122.4% | 725,749 | +94.5% | 0.01% | +100.0% |
| Q3 2019 | $5,785,000 | -54.8% | 373,064 | -49.9% | 0.00% | -50.0% |
| Q2 2019 | $12,789,000 | -11.9% | 744,549 | -17.4% | 0.01% | -11.1% |
| Q1 2019 | $14,516,000 | +205.7% | 901,681 | +177.7% | 0.01% | +200.0% |
| Q4 2018 | $4,748,000 | -89.8% | 324,651 | -87.3% | 0.00% | -78.6% |
| Q3 2018 | $46,440,000 | +20.1% | 2,556,019 | +11.5% | 0.01% | +27.3% |
| Q2 2018 | $38,680,000 | +82.6% | 2,292,932 | +112.0% | 0.01% | +10.0% |
| Q1 2018 | $21,187,000 | +37.1% | 1,081,636 | +41.7% | 0.01% | 0.0% |
| Q4 2017 | $15,459,000 | +40.1% | 763,136 | +20.1% | 0.01% | +25.0% |
| Q3 2017 | $11,035,000 | +128.2% | 635,468 | +68.3% | 0.01% | +166.7% |
| Q2 2017 | $4,836,000 | +50.7% | 377,551 | +52.3% | 0.00% | +50.0% |
| Q1 2017 | $3,210,000 | +6.6% | 247,882 | -18.7% | 0.00% | 0.0% |
| Q4 2016 | $3,010,000 | -48.6% | 304,891 | -37.2% | 0.00% | -50.0% |
| Q3 2016 | $5,858,000 | -18.8% | 485,122 | -42.0% | 0.00% | -20.0% |
| Q2 2016 | $7,216,000 | +11.3% | 836,355 | +22.2% | 0.01% | 0.0% |
| Q1 2016 | $6,482,000 | -34.3% | 684,663 | +20.2% | 0.01% | -28.6% |
| Q4 2015 | $9,870,000 | +35.5% | 569,672 | +5.0% | 0.01% | +16.7% |
| Q3 2015 | $7,283,000 | -45.4% | 542,375 | -8.3% | 0.01% | -33.3% |
| Q2 2015 | $13,347,000 | +19.9% | 591,203 | -24.2% | 0.01% | +28.6% |
| Q1 2015 | $11,133,000 | +52.8% | 779,826 | +3.3% | 0.01% | +75.0% |
| Q4 2014 | $7,286,000 | +69.5% | 755,257 | +59.8% | 0.00% | +33.3% |
| Q3 2014 | $4,298,000 | -26.5% | 472,731 | -20.2% | 0.00% | -25.0% |
| Q2 2014 | $5,847,000 | -16.7% | 592,152 | +7.2% | 0.00% | -20.0% |
| Q1 2014 | $7,018,000 | -36.0% | 552,527 | -24.5% | 0.01% | -37.5% |
| Q4 2013 | $10,961,000 | +25.1% | 731,369 | -7.8% | 0.01% | +33.3% |
| Q3 2013 | $8,760,000 | – | 793,536 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |